YH

Yourgene Health

www.yourgenehealth.com link_icon

Market Research Report: Yourgene Health



Company Overview



Name: Yourgene Health

Mission: To enable scientific advances to positively impact human health.

Founded: 2013

Founders: Initial details regarding founders are not specified.

Key People: James McCarthy, Acting Chief Executive Officer.

Headquarters: Skelton House, Manchester Science Park, Lloyd Street North, Manchester, M15 6SH, UK.

Number of Employees: No information is available.

Revenue: No information is available.

Known For: Yourgene Health is recognized as an international specialist in clinical diagnostics, primarily focusing on liquid biopsy through non-invasive prenatal testing (NIPT), sample preparation, and precision medicine.

Products



Reproductive Health


  • Products Offered:

  • IONA® Test

  • Yourgene® Cystic Fibrosis Assays


  • Description & Key Features:

  • IONA® Test: A non-invasive prenatal screening test used for detecting fetal anomalies.

  • Yourgene® Cystic Fibrosis Base Assay: Utilizes amplification-refractory mutation system technology for detecting point mutations, insertions, or deletions in DNA, with applications in carrier screening, newborn screening, and male factor infertility testing.


Precision Medicine


  • Products Offered:

  • Yourgene® DPYD


  • Description & Key Features:

  • Yourgene® DPYD: An in vitro diagnostic test for genotyping to identify cancer patients at risk of severe reactions to 5-Fluorouracil (5-FU) chemotherapy, designed to detect six clinically relevant variants in the DPD enzyme.


Oncology


  • Products Offered:

  • Cancer Precision Medicine Panel

  • Chemotherapy Resistance (DPYD)


  • Description & Key Features:

  • These products focus on evaluating genetic markers to aid in cancer treatment decisions and managing chemotherapy resistance.


Recent Developments



  • New Products Launched:

  • IVDR certification was achieved for the Yourgene® DPYD genotyping assay as the first product of its kind to conform with new EU IVDR requirements in November 2023.


  • New Features Added to Existing Products:

  • No specific new features mentioned apart from the conforming of products like the DPYD genotyping assay and the Cystic Fibrosis Base Assay to the new EU regulatory standards.


  • Partnerships and Acquisitions:

  • The company has grown strategically through several acquisitions:

  • 2014: Launch of the Premaitha Health brand.

  • 2016: Acquisition of Yourgene Bioscience to expand into the Asia market.

  • 2019: Acquisition of Elucigene Diagnostics.

  • 2020: Acquisitions of Ex5 Genomics and Coastal Genomics to enhance technology and geographic expansion.


Additional Information



Global Presence:
Yourgene Health operates internationally with offices located in Düsseldorf, Miami, Paris, Singapore, and Vancouver.

Technological Advances:
The company emphasizes disruptive technology in cell-free DNA testing, which includes next-generation size selection and fetal fraction enrichment.

Key Milestones:
  • Yourgene Health has transitioned from a single-product NIPT company to an international genomic medicine company with more than 100 products and services.


[For more detailed information about specific products, visit Yourgene Health's official website](https://yourgenehealth.com).

(Note: All information is based on the provided document and may be subject to changes not reflected in this report.)